Marinus Pharma (MRNS) Misses Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 7, 2023 4:01 PM ESTZTALMY® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022 Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fiscal year ending December 31, 2023 Second generation oral formulation development continues to advance based on encouraging Phase 1 data Actively recruiting Phase 3 clinical trials in refractory status epilepticus and tuberous sclerosis complex; data continues to be expected 2H 2023 and Q1 2024, respectively Phase 2 clinical trial of oral ganaxolone in PCDH-19 published in... More
